Mechanical Ventilation

Mechanical Ventilation: 2026 Evidence, Settings & Liberation

Current standard of care for the ventilated adult, organized by treatment area, with the trials behind each recommendation. ARDS-specific rescue (prone, ECMO) lives in the ARDS review.

Reviewed by the DosePilot Medical Team · Last reviewed: Jun 2026 · Independent — no industry funding
How to read this page. Each treatment area opens with the current approach, then the trials behind it (design, key results, limitations), and a short practical note (In practice). All settings and figures are taken from the cited primary sources (DOI + PMID). This page covers the general ventilated patient and liberation/weaning; ARDS-specific rescue therapies are summarized in the ARDS review. In practice notes are general guidance, not a substitute for clinical judgment.
How we verify evidence & editorial policy
Written and maintained by the DosePilot Medical Team. Recommendations are based on randomized controlled trials and current society guidelines (GRADE). Every citation is verified directly against PubMed (PMID) and the publisher DOI — no memory-based or AI-generated references. Each topic is peer-reviewed by the clinical team before publication and re-reviewed at least every 12 months or when major new evidence appears.

Funding & conflicts of interest. Produced independently; no industry funding was received for this content and contributors report no relevant financial conflicts of interest.
On this page
  1. Evidence timeline
  2. Modes & initial settings
  3. Lung-protective ventilation
  4. PEEP & oxygenation targets
  5. Sedation & spontaneous awakening
  6. Daily spontaneous breathing trial
  7. Extubation & post-extubation support
  8. NIV & high-flow nasal cannula
  9. Refractory hypoxemia
  10. Ventilator-associated pneumonia prevention
  11. Where it’s heading
  12. Bottom line
  13. FAQ
  14. Related DosePilot tools
  15. Guidelines & evidence basis
At a glance — current standard of care
AreaCurrent approachKey trial(s)
Tidal volume6 mL/kg predicted body weight; plateau ≤30; driving pressure <15ARMA; Amato
Non-ARDS VtLow ≈ intermediate (up to ~8) if plateau/DP safePReVENT
ModeNo mode superior; volume A/C initial; avoid SIMV for weaning—
PEEPModerate; higher only in moderate–severe ARDSBriel meta
RecruitmentAvoid aggressive recruitment + high-PEEP titration (harm)ART
AreaCurrent approachKey trial(s)
SedationLight (RASS −2 to 0); daily awakening; non-benzoABC trial
WeaningDaily SBT (PSV ≤8 or T-piece, 30 min–2 h)Subirà; ABC
ExtubationFailed cuff-leak (no leak) → steroids; airway/cough checkKuriyama
Post-extubationProphylactic HFNC (≈ NIV) in high-riskHernández
Avoid intubationHFNC first for hypoxemic failure; NIV for COPD/edemaFLORALI

1Evidence timeline (2000–2026)

2000ARMA / ARDSNet — tidal volume 6 vs 12 mL/kg cuts mortality (31% vs 40%); lung-protective ventilation is born
2004ALVEOLI — higher vs lower PEEP at the same low tidal volume: no overall difference
2008ABC trial — pairing daily spontaneous awakening + breathing trials (“wake up and breathe”) improves outcomes; LOVS & ExPress test higher PEEP
2010Briel meta-analysis — higher PEEP helps only moderate–severe ARDS, not milder disease
2013PROSEVA — prone positioning ≥16 h lowers mortality in severe ARDS (see ARDS review)
2015FLORALI — high-flow nasal cannula in acute hypoxemic failure; Amato — driving pressure is the variable most linked to survival
2016Hernández — after extubation, high-flow nasal cannula is non-inferior to NIV in high-risk patients
2017ART — aggressive recruitment + titrated high PEEP increases mortality; ATS/ACCP liberation guideline published
2018PReVENT — in patients without ARDS, low vs intermediate tidal volume makes no difference
2019Subirà — a 30-minute pressure-support SBT yields more extubations than a 2-hour T-piece trial
2022TIP-EX — in high-risk patients, PSV vs T-piece SBT: ventilator-free days no different; 2024 AARC spontaneous-breathing-trial guideline
2025–26Diaphragm-protective ventilation, mechanical power, and automated weaning move toward the bedside; no new mortality-changing mode

2Modes & initial settings

Current approach (2026)
No mode superior for mortality
Start most patients on volume assist-control (A/C) — it guarantees a set tidal volume — or a pressure mode per unit familiarity; no ventilator mode has been shown to improve mortality over another. Set the initial tidal volume by predicted body weight (from height and sex), not actual weight: 6–8 mL/kg PBW, respiratory rate ~16–20 to a normal-for-patient pH, PEEP 5 cmH₂O, and FiO₂ titrated to the oxygenation target. Avoid SIMV as a weaning mode — it prolongs weaning. Confirm tube position and check a plateau pressure early.
Evidence
—
Mode comparisons (A/C vs PSV vs SIMV). Randomized and observational comparisons find no mortality difference between assist-control, pressure-support, and other modes; the ventilator settings (tidal volume, plateau, PEEP) matter far more than the mode label. SIMV-based weaning was slower than pressure-support or T-piece weaning in classic trials, so it is not recommended for liberation.

Why predicted body weight. Lung size tracks height, not body mass; using actual weight in an obese patient delivers an injuriously large tidal volume. PBW (men 50 + 2.3 × [height in inches − 60]; women 45.5 + 2.3 × […]) is the denominator in every lung-protective target.

In practice

Default to volume A/C, set Vt by PBW (calculate from height), RR to match the patient’s baseline minute ventilation, PEEP 5, FiO₂ to target — then check a plateau pressure. Don’t switch to SIMV to “wean”; use daily SBTs instead (§6).

Sources (1)
  • Fan E, Zakhary B, Amaral A, et al. Liberation from mechanical ventilation in critically ill adults: an official ATS/ACCP clinical practice guideline. Ann Am Thorac Soc. 2017;14(3):441–443. DOI 10.1513/AnnalsATS.201612-993CME. PMID 28029806.

3Lung-protective ventilation (for everyone)

Current approach (2026)
RCT: Vt 6 mL/kg + plateau ≤30 (ARMA)RCT: non-ARDS low ≈ intermediate (PReVENT)
Ventilate to protect the lung in every patient, not only ARDS: target tidal volume ~6 mL/kg predicted body weight (range 4–8), keep plateau pressure ≤30 cmH₂O, and aim for a driving pressure (plateau − PEEP) <15 cmH₂O. In patients without lung injury, an intermediate tidal volume (up to ~8 mL/kg PBW) is acceptable provided plateau and driving pressure stay safe. Permit modest hypercapnia (“permissive hypercapnia”) to keep these limits.
Evidence — old → new
2000
ARMA / ARDSNet (the foundation). RCT, 861 patients with ALI/ARDS; 6 mL/kg vs 12 mL/kg PBW (plateau target ≤30 vs ≤50). Stopped early for benefit — in-hospital mortality 31.0% vs 39.8% and more ventilator-free days. Established low-tidal-volume ventilation as standard.
2015
Amato — driving pressure. Mediation analysis of 3,562 ARDS patients across 9 trials found driving pressure (ΔP = plateau − PEEP) was the ventilation variable most strongly associated with survival; a higher ΔP predicted higher mortality even when Vt and plateau were “protective”. Target ΔP <15 cmH₂O.
2018
PReVENT — non-ARDS. RCT, 961 ICU patients without ARDS; low (~6) vs intermediate (~10) mL/kg PBW. No difference in ventilator-free days (median 21 vs 21) or mortality. So in non-injured lungs, a strictly low Vt is not mandatory — but plateau and driving pressure limits still apply.

What changed. Lung protection spread from ARDS (ARMA) to the whole ICU, and the target shifted from tidal volume alone toward driving pressure as the unifying, lung-size-adjusted limit.

In practice

Set Vt ~6 mL/kg PBW, hold plateau ≤30 and ΔP <15. In a non-ARDS patient with safe pressures, don’t chase exactly 6 — but never exceed the pressure limits. Tolerate a higher CO₂ / lower pH to stay protective.

Sources (3)
  • Acute Respiratory Distress Syndrome Network (ARMA). Ventilation with lower tidal volumes for acute lung injury and ARDS. N Engl J Med. 2000;342(18):1301–1308. DOI 10.1056/NEJM200005043421801. PMID 10793162.
  • Amato MBP, Meade MO, Slutsky AS, et al. Driving pressure and survival in the acute respiratory distress syndrome. N Engl J Med. 2015;372(8):747–755. DOI 10.1056/NEJMsa1410639. PMID 25693014.
  • Simonis FD, et al (PReVENT). Effect of a low vs intermediate tidal volume strategy on ventilator-free days in ICU patients without ARDS. JAMA. 2018;320(18):1872–1880. DOI 10.1001/jama.2018.14280. PMID 30357256.

4PEEP & oxygenation targets

Current approach (2026)
RCT: higher PEEP only in moderate–severe ARDS (Briel)RCT: aggressive recruitment + high PEEP — harm (ART)
Begin at a moderate PEEP (~5 cmH₂O) and titrate up only when oxygenation demands it. Higher PEEP benefits moderate-to-severe ARDS (PaO₂/FiO₂ ≤200) but not mild or non-injured lungs. Do not perform aggressive lung-recruitment maneuvers with stepwise high-PEEP titration — this increased mortality. Target SpO₂ ~92–96%, avoiding both hypoxemia and sustained hyperoxia.
Evidence — old → new
2010
Briel meta-analysis (PEEP, individual-patient data). Pooled ALVEOLI, LOVS, and ExPress (2,299 patients). Higher PEEP did not improve hospital survival overall, but did improve survival in the subgroup with moderate–severe ARDS (PaO₂/FiO₂ ≤200). PEEP should be matched to disease severity.
2017
ART — recruitment can harm. RCT, 1,010 patients with moderate–severe ARDS; lung recruitment + compliance-titrated high PEEP vs low PEEP. The aggressive arm had higher 28-day mortality (55.3% vs 49.3%) and 6-month mortality, with more barotrauma and cardiac arrests during maneuvers. Aggressive recruitment is not recommended.

What changed. From “open the lung” enthusiasm to a measured stance: match PEEP to severity, and avoid aggressive recruitment. Oxygenation goals also tightened away from hyperoxia.

In practice

Start PEEP ~5 and raise it for moderate–severe ARDS using a PEEP/FiO₂ table; don’t run stepwise recruitment-to-high-PEEP protocols. Keep SpO₂ 92–96% and wean FiO₂ off 100% promptly.

Sources (2)
  • Briel M, Meade M, Mercat A, et al. Higher vs lower PEEP in patients with ALI and ARDS: systematic review and meta-analysis. JAMA. 2010;303(9):865–873. DOI 10.1001/jama.2010.218. PMID 20197533.
  • Writing Group for the ART Investigators. Effect of lung recruitment and titrated PEEP vs low PEEP on mortality in moderate-to-severe ARDS. JAMA. 2017;318(14):1335–1345. DOI 10.1001/jama.2017.14171. PMID 28973363.

5Sedation & spontaneous awakening

Current approach (2026)
RCT: paired SAT + SBT improves outcomes (ABC)Guideline: light sedation, ABCDEF
Target light sedation (RASS −2 to 0) and perform a daily spontaneous awakening trial (SAT) — interrupt sedatives and reassess — then proceed to a breathing trial if the patient tolerates it. Prefer non-benzodiazepine sedation (propofol or dexmedetomidine). Treat pain first, monitor sedation (RASS) and delirium (CAM-ICU), and embed this in the ABCDEF bundle. Deep sedation prolongs ventilation and worsens outcomes.
Evidence
2008
ABC trial (“wake up and breathe”). RCT, 336 patients; a paired protocol of daily SAT + SBT vs SBT alone (usual sedation). The paired group had more ventilator-free days (14.7 vs 11.6), shorter ICU/hospital stay, and lower 1-year mortality (44% vs 55%; HR 0.68). Linking sedation interruption to the breathing trial is the engine of liberation.

Why it matters. Sedation depth drives ventilator days; a patient who is awake enough to breathe and follow commands is a patient who can be assessed for extubation. The SAT is the gateway to the SBT.

In practice

Each morning: confirm pain control, stop/lighten sedation (SAT), and if the patient is calm and awake, move straight to an SBT. Use propofol or dexmedetomidine over benzodiazepines; track RASS and CAM-ICU.

Sources (1)
  • Girard TD, Kress JP, Fuchs BD, et al (ABC trial). Efficacy and safety of a paired sedation and ventilator weaning protocol (Awakening and Breathing Controlled trial): a randomised controlled trial. Lancet. 2008;371(9607):126–134. DOI 10.1016/S0140-6736(08)60105-1. PMID 18191684.

6Daily spontaneous breathing trial (SBT)

Current approach (2026)
RCT: lighter/shorter SBT → more extubation (Subirà)Guideline: daily SBT (ATS/ACCP, AARC 2024)
Once the underlying cause is improving and the patient is oxygenating on low support, hemodynamically stable, and awake, do a daily SBT: low-level pressure support (≤8 cmH₂O) or a T-piece, for 30 minutes to 2 hours. A short pressure-support trial yields at least as many successful extubations as a longer T-piece trial. Judge tolerance clinically (respiratory rate, comfort, gas exchange) rather than by weaning indices alone.
Evidence — old → new
2019
Subirà — PSV beats T-piece for extubation. RCT, 1,153 patients; 30-min pressure support (8 cmH₂O) vs 2-h T-piece. Successful extubation was higher with PSV (82.3% vs 74.0%; difference 8.2 points), with no significant increase in reintubation. A lighter, shorter SBT liberates more patients.
2022
TIP-EX — high-risk SBT trial. Multicenter RCT in patients at high risk of extubation failure (older, chronic cardiac/respiratory disease); pressure support vs T-piece. The primary outcome — ventilator-free days at day 28 — did not differ, and reintubation was similar (14.9% vs 13.6%) — so in high-risk patients either technique is reasonable, while PSV remains attractive for the general population.

What changed. The SBT shortened and lightened — a 30-minute pressure-support trial is now a standard option, replacing the older mandatory 2-hour T-piece for most patients.

In practice

Screen daily; when ready, run a 30-minute SBT at PSV 8 / PEEP 0–5. If the patient stays comfortable with stable vitals and gas exchange, move to the airway/extubation assessment (§7). Pair the SBT with the morning SAT.

Sources (3)
  • Subirà C, et al. Effect of pressure support vs T-piece ventilation strategies during spontaneous breathing trials on successful extubation. JAMA. 2019;321(22):2175–2182. DOI 10.1001/jama.2019.7234. PMID 31184740.
  • Thille AW, et al; REVA Research Network (TIP-EX). Spontaneous-breathing trials with pressure-support ventilation or a T-piece. N Engl J Med. 2022;387(20):1843–1854. DOI 10.1056/NEJMoa2209041. PMID 36286317.
  • Fan E, Zakhary B, Amaral A, et al. Liberation from mechanical ventilation: ATS/ACCP clinical practice guideline. Ann Am Thorac Soc. 2017;14(3):441–443. DOI 10.1513/AnnalsATS.201612-993CME. PMID 28029806.

7Extubation & post-extubation support

Current approach (2026)
RCT: post-extubation HFNC ≈ NIV in high-risk (Hernández)Meta: cuff-leak positive → steroids (Kuriyama)
After a passed SBT, assess the airway before pulling the tube: mental status, cough strength, secretion burden, and a cuff-leak test in patients at risk of laryngeal edema. If there is little or no cuff leak (a failed cuff-leak test → high risk of laryngeal edema), give IV corticosteroids ≥4 hours before extubation. In high-risk patients, apply prophylactic high-flow nasal cannula or NIV immediately after extubation to prevent reintubation — HFNC is non-inferior to NIV and better tolerated; reserve NIV for hypercapnic/COPD/heart-failure phenotypes.
Evidence — old → new
2016
Hernández — HFNC vs NIV after extubation (high-risk). RCT, 604 high-risk patients; prophylactic HFNC vs NIV for 24 h after extubation. HFNC was non-inferior for reintubation (within 72 h) and better tolerated, with fewer adverse effects. (A companion trial showed HFNC beat conventional oxygen in low-risk patients.)
meta
Cuff-leak test & steroids (Kuriyama). Systematic review/meta-analysis: in adults at high risk of laryngeal edema — a failed cuff-leak test (little or no leak around the deflated cuff) — prophylactic corticosteroids given ≥4 h before extubation reduced post-extubation stridor and reintubation. Benefit is confined to this high-risk (reduced/absent leak) subgroup — do not steroid-treat everyone.

What changed. Extubation became a two-step decision (breathing and airway), and HFNC displaced NIV as the default post-extubation support for most high-risk patients.

In practice

After a passed SBT, confirm the patient can protect the airway and clear secretions; check a cuff leak in at-risk patients and give steroids ≥4 h before extubation if the leak is reduced or absent (failed test). Extubate high-risk patients straight onto HFNC (or NIV if COPD/CHF/hypercapnic).

Sources (2)
  • Hernández G, et al. Effect of postextubation high-flow nasal cannula vs noninvasive ventilation on reintubation and postextubation respiratory failure in high-risk patients. JAMA. 2016;316(15):1565–1574. DOI 10.1001/jama.2016.14194. PMID 27706464.
  • Kuriyama A, Umakoshi N, Sun R. Prophylactic corticosteroids for prevention of postextubation stridor and reintubation in adults: systematic review and meta-analysis. Chest. 2017;151(5):1002–1010. DOI 10.1016/j.chest.2017.02.017. PMID 28232056.

8NIV & high-flow nasal cannula (avoiding intubation)

Current approach (2026)
Guideline: NIV — COPD & cardiogenic edemaRCT: HFNC in hypoxemic failure (FLORALI)
NIV is first-line and reduces intubation and mortality in COPD exacerbation with respiratory acidosis and cardiogenic pulmonary edema. For de novo acute hypoxemic respiratory failure (e.g., pneumonia), high-flow nasal cannula is a reasonable first device; NIV here is less certain and risks harm from large tidal volumes and delayed intubation. Whichever is chosen, monitor closely and do not delay intubation if the patient is not improving (track the ROX index).
Evidence
2015
FLORALI — HFNC in hypoxemic failure. RCT, 310 patients with non-hypercapnic acute hypoxemic respiratory failure; HFNC vs standard oxygen vs NIV. The primary outcome (intubation) did not differ significantly overall; HFNC had lower 90-day mortality (a secondary endpoint), and in a post-hoc subgroup with PaO₂/FiO₂ ≤200 HFNC reduced intubation. NIV — delivered at high tidal volume — showed no benefit and a mortality signal of concern.

Phenotype matters. NIV’s strong evidence is in hypercapnic COPD and cardiogenic edema; in de novo hypoxemia the data favor HFNC and caution against NIV. Failing NIV/HFNC late is dangerous — set explicit re-assessment points.

In practice

COPD flare or flash pulmonary edema → NIV. Hypoxemic pneumonia/ARDS-spectrum → HFNC first. Re-check at 1–2 h (work of breathing, ROX); if not improving, intubate rather than persist.

Sources (1)
  • Frat JP, Thille AW, Mercat A, et al (FLORALI). High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med. 2015;372(23):2185–2196. DOI 10.1056/NEJMoa1503326. PMID 25981908.

9Refractory hypoxemia (when protective settings aren’t enough)

Current approach (2026)
RCT: prone positioning in severe ARDS (PROSEVA)
When hypoxemia is refractory despite lung-protective settings and appropriate PEEP, escalate using the ARDS toolkit: prone positioning ≥16 h/day for moderate–severe ARDS, neuromuscular blockade for early severe ARDS with ventilator dyssynchrony, and veno-venous ECMO for the most severe, refractory cases at experienced centers. These are detailed in the ARDS review.
Evidence
2013
PROSEVA — prone positioning. RCT, 466 patients with severe ARDS (PaO₂/FiO₂ <150); early prone ≥16 h vs supine. 28-day mortality 16.0% vs 32.8% (HR 0.39) — one of the largest mortality reductions in ARDS. Apply early in severe disease with a trained team.

Scope. Refractory hypoxemia management overlaps the ARDS review; this section is a pointer so the ventilated-patient workflow is complete. See ARDS for proning logistics, NMB dosing, and ECMO criteria (EOLIA/CESAR).

In practice

If PaO₂/FiO₂ stays <150 on protective settings, prone early (≥16 h blocks), consider a short course of neuromuscular blockade, and refer to ECMO for refractory cases — see the ARDS review for the detail.

Sources (1)
  • Guérin C, Reignier J, Richard JC, et al (PROSEVA). Prone positioning in severe acute respiratory distress syndrome. N Engl J Med. 2013;368(23):2159–2168. DOI 10.1056/NEJMoa1214103. PMID 23688302.

10Ventilator-associated pneumonia prevention

Current approach (2026)
Bundle / quality-improvement evidence
Reduce ventilator-associated events with a care bundle: elevate the head of bed 30–45°, perform daily SAT + SBT to shorten ventilation, provide oral care, use subglottic secretion drainage tubes when ventilation beyond 48–72 h is expected, maintain the circuit (avoid unnecessary changes), and apply VTE and stress-ulcer prophylaxis as indicated. The single most effective measure is minimizing days on the ventilator — which is why sedation-lightening and daily SBTs are central.
Evidence
bundle
Ventilator bundles. Individual elements (semi-recumbent positioning, subglottic drainage, sedation minimization, daily SBT) and combined bundles reduce VAP and ventilator days in trials and quality-improvement cohorts. Routine chlorhexidine oral care is now debated — meta-analyses signal increased mortality in non-cardiac-surgery ICU patients, so some guidance now favors removing it from the bundle outside cardiac surgery.

Why it matters. VAP prolongs ventilation and ICU stay; most prevention value comes from getting the patient off the ventilator sooner, tying VAP prevention directly to the liberation workflow above.

In practice

Keep the head up, run daily SAT/SBT, use subglottic-drainage tubes for anticipated prolonged ventilation, and do oral care; revisit local chlorhexidine policy given the harm signal. Document a daily “can this patient be extubated?” check.

Sources (1)
  • Fan E, Zakhary B, Amaral A, et al. Liberation from mechanical ventilation: ATS/ACCP clinical practice guideline. Ann Am Thorac Soc. 2017;14(3):441–443. DOI 10.1513/AnnalsATS.201612-993CME. PMID 28029806.

11Where it’s heading (2026)

Diaphragm-protective ventilation. Both over-assist (disuse atrophy) and under-assist (load-induced injury) harm the diaphragm; titrating support to preserve safe respiratory effort is an active target.

Mechanical power & P-SILI. Beyond driving pressure, the total energy delivered (mechanical power) and patient self-inflicted lung injury from vigorous spontaneous effort are being tested as modifiable harms.

Automated & closed-loop weaning. Automated SBT/weaning modes and protocols aim to standardize liberation and cut ventilator days; esophageal-pressure–guided PEEP (EPVent-2) was neutral and remains investigational.

12Bottom line — the ventilated-patient workflow

  1. Set protective from minute one — Vt ~6 mL/kg predicted body weight, plateau ≤30, driving pressure <15; volume A/C is a fine default.
  2. Non-ARDS: intermediate Vt is acceptable if plateau/ΔP are safe (PReVENT).
  3. PEEP to severity — moderate by default; higher only in moderate–severe ARDS; avoid aggressive recruitment (ART harm). SpO₂ 92–96%.
  4. Light sedation + daily SAT (non-benzodiazepine; ABCDEF).
  5. Daily SBT — PSV ≤8 or T-piece, 30 min–2 h; pair with the SAT.
  6. Extubation = breathing + airway — failed cuff-leak (little/no leak) → steroids ≥4 h before; assess cough/secretions.
  7. Post-extubation: prophylactic HFNC (≈ NIV) in high-risk; NIV for COPD/CHF.
  8. Avoid intubation: HFNC first for hypoxemic failure; NIV for COPD/edema; don’t delay intubation if failing.
  9. Refractory hypoxemia: prone ≥16 h, NMB, ECMO — see the ARDS review.
  10. Prevent VAP by getting off the ventilator sooner: head up, daily SAT/SBT, subglottic drainage.

13FAQ

What tidal volume should I set on the ventilator?
About 6 mL/kg of predicted body weight (calculated from height and sex, not actual weight), keeping plateau pressure ≤30 cmH₂O and driving pressure (plateau − PEEP) <15 cmH₂O. In patients without ARDS, an intermediate volume (up to ~8 mL/kg PBW) is acceptable if the pressures stay safe (PReVENT).
Which ventilator mode is best?
No mode has been shown to improve mortality over another — settings matter more than the mode. Volume assist-control is a reasonable default. Avoid SIMV as a weaning mode because it prolongs weaning.
How is a patient weaned from the ventilator?
Target light sedation and run a daily spontaneous awakening trial (SAT) paired with a daily spontaneous breathing trial (SBT). The ABC trial showed this “wake up and breathe” approach increases ventilator-free days and lowers 1-year mortality.
Pressure support or T-piece for the breathing trial?
Either is acceptable. A 30-minute pressure-support trial (8 cmH₂O) produced more successful extubations than a 2-hour T-piece trial in the general population (Subirà, 82.3% vs 74.0%); in high-risk patients the two are comparable.
Should I use higher or lower PEEP?
Start moderate (~5) and raise PEEP only as oxygenation demands. Higher PEEP helps moderate-to-severe ARDS (PaO₂/FiO₂ ≤200) but not milder disease (Briel). Avoid aggressive recruitment maneuvers with high-PEEP titration — they increased mortality (ART).
HFNC or NIV after extubation?
In high-risk patients, prophylactic high-flow nasal cannula is non-inferior to NIV for preventing reintubation and is better tolerated (Hernández). Reserve NIV for hypercapnic, COPD, or heart-failure phenotypes.
HFNC or NIV to avoid intubation in respiratory failure?
NIV is first-line for COPD exacerbation and cardiogenic pulmonary edema. For de novo acute hypoxemic failure (e.g., pneumonia), high-flow nasal cannula is the better first device (FLORALI); monitor closely and do not delay intubation if the patient is not improving.

15Guidelines & evidence basis

Badges summarize each recommendation’s basis: Guideline: strong Guideline: conditional RCT benefit RCT neutral RCT harm. Guideline strengths use the GRADE classes quoted from the documents below.

Guidelines referenced (2)
  • Fan E, Zakhary B, Amaral A, et al. Liberation from Mechanical Ventilation in Critically Ill Adults: An Official ATS/ACCP Clinical Practice Guideline. Ann Am Thorac Soc. 2017;14(3):441–443. DOI 10.1513/AnnalsATS.201612-993CME. PMID 28029806. — daily SBT with low-level pressure support, protocolized sedation lightening (SAT), post-extubation NIV in high-risk patients, and the cuff-leak test.
  • Roberts KJ, Goodfellow LT, Battey-Muse CM, et al (AARC). Clinical practice guideline: spontaneous breathing trials for liberation from adult mechanical ventilation. Respir Care. 2024;69(7):891–901. DOI 10.4187/respcare.11735. PMID 38443142. — guidance on SBT technique and duration.

Disclaimer. This page is an educational summary of published evidence for clinicians and is not a substitute for individual clinical judgment or institutional protocols. Settings, targets, and thresholds are taken from the cited trials and guidelines; verify against current device labeling, local guidelines, and patient-specific factors before applying. “In practice” notes are general practical guidance. Recommendation strengths are quoted from the cited guidelines (GRADE). Reviewed by the DosePilot Medical Team (Jun 2026); all citations verified against PubMed (PMID) and DOI on 2026-06-23.